

SHORT REPORT

Genetic screening of Congenital Short Bowel Syndrome patients confirms *CLMP* as the major gene involved in the recessive form of this disorder

Maria M Alves^{*1}, Danny Halim^{1,10}, Reza Maroofian^{2,10}, Bianca M de Graaf¹, Raoul Rooman^{3,11}, Christine S van der Werf⁴, Els Van de Vijver³, Mohammad YV Mehrjardi^{5,6}, Majid Aflatoonian⁷, Barry A Chioza², Emma L Baple^{2,8}, Mohammadreza Dehghani^{5,9}, Andrew H Crosby² and Robert MW Hofstra¹

Congenital short bowel syndrome (CSBS) is an intestinal pediatric disorder, where patients are born with a dramatic shortened small intestine. Pathogenic variants in *CLMP* were recently identified to cause an autosomal recessive form of the disease. However, due to the rare nature of CSBS, only a small number of patients have been reported to date with variants in this gene. In this report, we describe novel inherited variants in *CLMP* in three CSBS patients derived from two unrelated families, confirming *CLMP* as the major gene involved in the development of the recessive form of CSBS.

European Journal of Human Genetics (2016) 24, 1627–1629; doi:10.1038/ejhg.2016.58; published online 29 June 2016

INTRODUCTION

During embryogenesis, the small intestine experiences major growth expanding several times the total length of the whole body. This is a complex process that starts around the fifth week of human development, when the midgut forms a simple linear tube that runs down the midline of the embryo, and is completed by the twentieth week of development.¹ Several pathways have been reported to have a role in intestinal elongation,² but to date the molecular mechanism(s) responsible for this process remains unclear.

In congenital short bowel syndrome (CSBS), intestinal elongation is impaired and patients are born with a substantially shortened small intestine (~50 cm in length instead of 250 cm in a normal counterpart).³ It is a rare disorder for which no cure is available. Total parenteral nutrition is required for long-term survival, but despite considerable efforts to improve treatment, most patients die of starvation or sepsis within the first few days of life.⁴ CSBS was first described by Hamilton *et al.*³ and it has always been considered to have a genetic cause.³ However, it was only recently that two genes were identified as the cause of CSBS: *CLMP* and *FLNA*.^{5,6} *CLMP* encodes for the Coxsackie and adenovirus receptor-like membrane protein, an adhesion molecule that co-localizes with tight junction proteins, but whose function is still unknown.⁷ *FLNA* encodes for Filamin-A, an actin-binding protein known to regulate cell shape and to control cell signaling and migration.⁸ Pathogenic variants present in *CLMP* and *FLNA* have been linked to the recessive and X-linked forms of CSBS, respectively.

Here, we report the genetic screening of three CSBS patients derived from two unrelated families, and describe the identification of three novel variants in *CLMP*.

MATERIAL AND METHODS

Patient information

In this study, three female patients diagnosed with CSBS were investigated (Table 1). Two of these patients were siblings of consanguineous descent (P1 and P2). The third patient (P3) has been previously described, when a *de novo* translocation was found between chromosome 2 and 11 (46,XX,t(2,11)(q32.2,p12)).⁹ However, no gene was identified as the causative factor at that time. A complete description of the patients can be found in Supplementary Data.

Written informed consent was given by the two families reported, and ethical approval was obtained from the Erasmus Medical Center ethical committee (Medisch Ethische Toetsings commissie - METc 2009/364, ABR nr: NL31708.042.10).

Genetic analysis

Genomic DNA was isolated from peripheral blood lymphocytes using standard methods. Exons 1–7 of *CLMP* (ENST00000448775) were amplified using 30 ng of genomic DNA as described before.⁵ PCR products were purified (ExoSap-IT – GE Healthcare, Eindhoven, The Netherlands), and Sanger sequencing was performed with dye labeled primers (forward and reverse; Big Dye Terminator v3.1 Sequencing Kit, Applied Biosystems, Bleiswijk, The Netherlands) on an ABI 3130XL genetic analyzer (Applied Biosystems). Sanger reads were analyzed using SeqScape software (Fisher Scientific, Landsmeer, The Netherlands) and compared with the reference *CLMP* genomic sequence (ENSG00000166250). Genetic data were submitted to ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) and the following

¹Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; ²University of Exeter Medical School, RILD Wellcome Wolfson Centre, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK; ³Department of Pediatrics, University Hospital of Antwerp, Antwerp, Belgium; ⁴Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands; ⁵Biomedical and Clinical Genetic Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; ⁶Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; ⁷Department of Pediatrics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; ⁸Faculty of Medicine, University of Southampton, Southampton, UK; ⁹Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

*Correspondence: Dr MM Alves, Department of Clinical Genetics, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Tel +31-10-7037643; E-mail: m.alves@erasmusmc.nl

¹⁰These authors contributed equally to this work.

¹¹Current address: PendoCon, Putte, Belgium.

Received 16 October 2015; revised 23 April 2016; accepted 4 May 2016; published online 29 June 2016

Table 1 Clinical and molecular features of the CSBS patients included in this study

	P1	P2	P3
Gender	Female	Female	Female
Age of diagnostic	3 months	38 days	1 week
Ethnicity	Iranian	Iranian	Caucasian
Consanguinity	+	+	No
Malrotation	+	+	+
Length of the small intestine (cm)	76	26	50
Additional features	Intestinal dysmotility UPJO	Intestinal dysmotility UPJO	Very mild mental retardation
<i>CLMP</i> variants	c.508C>T; p.(R170*)	c.508C>T; p.(R170*)	c.410G>A; p.(C137Y) c.29-2 A>G
Zygosity	Homozygous	Homozygous	Heterozygous (two unphased variants)

Abbreviations: CSBS, congenital short bowel syndrome; UPJO, ureteropelvic junction obstruction.




Figure 1 Genetic analysis of three CSBS patients. **(a)** Pedigree of the two families included in this study with Sanger sequencing results showing the presence of variants in *CLMP*. **(b)** Conservation alignments showed that the missense variant p.(C137Y) leads to a change of a cysteine residue highly conserved among vertebrates. **(c)** CHO-K1 cells transfected with constructs expressing wild-type (WT) *CLMP* or the p.(C137Y) variant show different cellular distribution of *CLMP*. While the WT protein normally localizes to the tight junctions (see arrows), the mutated protein has a punctuated distribution through the cytoplasm. Scale bars: 30 μm. **(d)** Splicing predictions suggested that the intronic variant identified in patient 3 likely affects normal splicing, as it is predicted to disrupt an acceptor-splicing site (c.29-2A>G). **(e)** Schematic overview of all the variants identified to date in *CLMP*. In black are the variants reported in this report, whereas in red are the variants previously described. **b** and **d** were generated using Alamut prediction software (Interactive Biosoftware, Rouen, France).

accession numbers were obtained: SCV000264793 [p.(R170*)] and SCV000264792 [p.(C137Y) and (c.29-2A>G)].

Expression vectors

Generation of the expression vectors used is described in Supplementary Data.

Immunofluorescence

Chinese hamster cells (CHO-K1) were cultured as described before.⁵ Five hundred thousand cells were seeded in a 6-well plate, and transiently transfected with pcDNA-HA-CLMP WT or pcDNA-HA-CLMP C137Y expressing vectors, using GeneJuice (Millipore, Amsterdam, The Netherlands) as transfection reagent. Twenty four hours after transfection, immunofluorescence was performed as previously described.⁵ Images were taken in a Leica (AOBS) microscope, and analyzed with the Leica LAS AF Lite software (Leica Microsystems B. V., Eindhoven, The Netherlands).

RESULTS AND DISCUSSION

As the three patients included in this study are females, an X-linked pattern of inheritance involving *FLNA* was considered unlikely, and only *CLMP* was screened. In all patients, we identified previously unreported variants in *CLMP*. None of these variants are listed in any of the available human genome variant databases. Patients P1 and P2 possess a homozygous nonsense variant in exon 4 [c.508C>T; p.(R170*)], leading to the appearance of an early stop codon (Figure 1a). This nonsense variant was inherited from the parents, who were found to be heterozygous. Patient P3 has two unphased heterozygous variants in *CLMP*. Although we suspect that both variants were inherited from the parents, we were unable to investigate segregation in the family due to unavailability of parental DNA. In this patient, a missense variant located in exon 4 was identified leading to an amino acid substitution [c.410G>A; p.(C137Y)], together with a possible splice site variant located two base pairs upstream of exon two (c.29-2A>G) (Figure 1a). Prediction programs used to infer pathogenicity (PolyPhen-2, MutationTaster, SIFT, Human Splicing Finder and Alamut Visual) showed that both variants are likely to disturb protein function. The C137Y variant is located in a highly conserved region present in all mammals (Figure 1b), and *in vitro* assays showed that it affects the cellular localization of CLMP to the tight junctions (Figure 1c). The c.29-2A>G variant is predicted to disrupt normal splicing of exon 2 of *CLMP* (Figure 1d). Considering that both variants likely affect CLMP function, we believe that the *de novo* translocation previously identified in patient P3⁹ is an independent event unrelated to CSBS.

Currently, only seven patients have been described carrying pathogenic variants in *CLMP*.⁵ All the variants reported were loss of function, leading to the absence of CLMP or to the expression of

a mutant protein with a disrupted function (Figure 1e). In this report, we expand the mutational spectrum of *CLMP* variants involved in CSBS, consolidating the involvement of this gene in the development of the recessive form of this disease. We also show that it might be worthwhile to screen previously described patients for whom an X-linked pattern of inheritance was disregarded, for the presence of variants in *CLMP*, as this might shed some light on the genetic basis of the disease in these cases. To date, the role of *CLMP* in intestinal elongation is still largely unknown, making it difficult to determine the molecular mechanisms underlying the development of CSBS. We believe that the results here described reinforce the need to further study the role of *CLMP* in intestinal elongation, as this might contribute for the development of new therapeutic strategies for CSBS patients.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We would like to thank all the families involved in this study. We would also like to thank Katherine MacKenzie for technical assistance with the confocal microscope. In addition, we would like to dedicate this short report in memory of the pediatric gastroenterologist involved in the diagnosis and care of one of the patients described, Dr André Deprettere. This study was supported by a grant from the Stichting Sophia Kinderziekenhuis Fonds (MMA and RMWH), a Mrace grant from the Erasmus University Medical Center (RMWH), and by the Newlife Foundation, as well as the MRC, UK (AHC).

- 1 Moore KL, Persaud TVN: *The Developing Human: Clinically Oriented Embryology*. Philadelphia: Saunders, 2003.
- 2 van der Werf CS, Halim D, Verheij JB, Alves MM, Hofstra RM: Congenital short bowel syndrome: from clinical and genetic diagnosis to the molecular mechanisms involved in intestinal elongation. *Biochim Biophys Acta* 2015; **1852**: 2352–2361.
- 3 Hamilton JR, Reilly BJ, Morecki R: Short small intestine associated with malrotation: a newly described congenital cause of intestinal malabsorption. *Gastroenterology* 1969; **56**: 124–136.
- 4 Howard L, Ament M, Fleming CR, Shike M, Steiger E: Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States. *Gastroenterology* 1995; **109**: 355–365.
- 5 van der Werf CS, Wabbersen TD, Hsiao NH *et al*: CLMP is required for intestinal development, and loss-of-function mutations cause congenital short-bowel syndrome. *Gastroenterology* 2012; **142**: 453–462.
- 6 van der Werf CS, Sribudiani Y, Verheij JB *et al*: Congenital short bowel syndrome as the presenting symptom in male patients with *FLNA* mutations. *Genet Med* 2013; **15**: 310–313.
- 7 Raschperger E, Engstrom U, Pettersson RF, Fuxe J: CLMP, a novel member of the CTX family and a new component of epithelial tight junctions. *J Biol Chem* 2004; **279**: 796–804.
- 8 Robertson SP, Filamin A: Phenotypic diversity. *Curr Opin Genet Dev* 2005; **15**: 301–307.
- 9 de Backer AI, Parizel PM, de Schepper A, Vaneerdeweg W: A patient with congenital short small bowel associated with malrotation. *J Belge Radiol* 1997; **80**: 71–72.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)